The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar
• 2 Dec 2018
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the results of the TOURMALINE-MM3 trial (NCT02181413) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in newly diagnosed multiple myeloma.
